Xbp1-driven lipid metabolism promotes immunosuppression in lung cancer: Jianpi Chutan Jiedu formula reshapes metabolic-immune crosstalk
- 15 February 2026
- journal article
- Published by Elsevier in Phytomedicine
- Vol. 153, 157973
Abstract
No abstract availableKeywords
Funding Information
- Natural Science Foundation Project of Chongqing, Chongqing Science and Technology Commission
- Natural Science Foundation of Chongqing Municipality (CSTB2022NSCQ-MSX1564)
This publication has 70 references indexed in Scilit:
- Syndecan-4 promotes gastric cancer progression through activating TGF-β1 induced lipid reprogramming and contributes positive loop circuitsDiscover Oncology, 2025
- Immunomodulatory effects of traditional chinese medicine on cancer: insights from network pharmacology and single-cell RNA sequencing data on the treatment of lung adenocarcinoma with shenling baizhu powderFunctional & Integrative Genomics, 2025
- Lung cancer research and treatment: global perspectives and strategic calls to actionAnnals of Oncology, 2024
- ALKBH5‐Mediated m6A Modification of XBP1 Facilitates NSCLC Progression Through the IL‐6–JAK–STAT3 PathwayMolecular Carcinogenesis, 2024
- Investigation of the mutual crosstalk between ER stress and PI3K/AKT/mTOR signaling pathway in iron overload-induced liver injury in chicksBioMetals, 2024
- CircSETD3 mediates acquired resistance to gefitinib in non-small lung cancer cells by FXR1/ECT2 pathwayThe International Journal of Biochemistry & Cell Biology, 2022
- Cancer cell-intrinsic XBP1 drives immunosuppressive reprogramming of intratumoral myeloid cells by promoting cholesterol productionCell Metabolism, 2022
- The role of lipids in cancer progression and metastasisCell Metabolism, 2022
- Targeting YAP1/TAZ in nonsmall‐cell lung carcinoma: From molecular mechanisms to precision medicineInternational Journal of Cancer, 2022
- Berberine reduces hepatic ceramide levels to improve insulin resistance in HFD-fed mice by inhibiting HIF-2αBiomedicine & Pharmacotherapy, 2022